Welcome to our dedicated page for Axogen SEC filings (Ticker: AXGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Axogen, Inc. (NASDAQ: AXGN) filings with the U.S. Securities and Exchange Commission, along with AI-assisted summaries to help interpret key disclosures. Axogen is a Minnesota-incorporated medical technology company focused on peripheral nerve repair and regeneration, and its filings offer detailed insight into financial performance, regulatory milestones, and corporate governance.
Through Axogen’s annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can review audited and interim financial statements, risk factors, management’s discussion and analysis, and information on its portfolio of peripheral nerve repair products, including Avance (acellular nerve allograft-arwx), Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. These reports also discuss regulatory processes, reimbursement trends, and non-GAAP measures such as EBITDA and Adjusted EBITDA.
Current reports on Form 8-K capture material events, such as Axogen’s announcements regarding FDA review timelines and approval of the Biologics License Application for Avance, quarterly financial results, changes to executive compensation arrangements, and outcomes of annual shareholder meetings. Regulation FD disclosures within 8-K filings often furnish press releases and investor presentations related to earnings and regulatory updates.
Investors can also use this page to track proxy materials and shareholder vote results on matters like director elections, long-term incentive plans, advisory votes on executive compensation, and auditor ratification. Where available, Form 4 and other insider transaction filings can be consulted to monitor trading activity by directors and officers.
The platform’s AI-powered tools summarize lengthy filings, highlight important sections, and surface items such as Avance BLA developments, risk factor changes, and capital structure information, helping readers navigate Axogen’s SEC reporting more efficiently.
Axogen executive Marc Began, EVP & General Counsel, acquired 22,500 shares of Axogen common stock on 12/04/2025 at a reported price of $0 per share. According to the explanation, these shares were issued upon the attainment of certain performance criteria, indicating a performance-based equity award rather than an open-market purchase. Following this transaction, Began beneficially owns 40,785 shares of Axogen common stock.
Axogen, Inc. reported that its Compensation Committee approved higher pay and updated restrictive covenants for Chief Financial Officer Lindsey Hartley. Effective January 1, 2026, her annual base salary will increase by 7%, and her target bonus opportunity under the company’s annual incentive program will rise from 50% to 60% of her annual base salary. The company and Ms. Hartley also entered into an Amended and Restated Confidentiality, Intellectual Property, Non-Competition and Non-Solicitation Agreement, effective December 5, 2025, which includes a two-year post-employment non-competition covenant, while her other compensatory arrangements remain unchanged.
Axogen, Inc. announced that the U.S. Food and Drug Administration has approved its Biologics License Application for Avance® (acellular nerve allograft-arwx), a nerve repair product. Some indications, including sensory nerve discontinuities greater than 25 mm and mixed and motor nerve discontinuities, were cleared under the FDA’s Accelerated Approval pathway based on improvements in static two-point discrimination in smaller sensory nerve gaps. Continued approval for these uses depends on confirmatory studies that verify and describe clinical benefit. The company expects the licensed Avance product to be commercially available in early second quarter 2026, while Avance remains available under the current tissue framework until then.
Axogen (AXGN) insider activity: Director William Burke reported option exercises and open‑market sales executed under a Rule 10b5‑1(c) plan adopted March 14, 2025. On 11/10/2025, he exercised stock options at $8.14 to acquire 19,227 shares, then sold 19,227 shares at a weighted average price of $24.01, with trades ranging from $24.00 to $24.10. On 11/11/2025, he exercised options at $8.14 for 3,591 shares and sold 3,591 shares at a weighted average price of $24.018, with trades from $24.00 to $24.13.
Following these transactions, he directly owned 100 shares. The exercised options carried a $8.14 exercise price and an expiration of July 11, 2032, from a grant that vested in three equal annual installments on the annual anniversary of the grant date, July 11, 2022.
Axogen (AXGN) Form 4: Director William Burke reported option exercises and matched open‑market sales executed under a Rule 10b5‑1(c) trading plan adopted March 14, 2025. On 11/05/2025, he exercised 11,431 stock options at $8.14 and sold 11,431 shares at a weighted average price of $24.048, with trades ranging from $24.00 to $24.25. On 11/06/2025, he exercised 5,347 options at $8.14 and sold 5,347 shares at a weighted average of $24.008, with trades from $24.00 to $24.06.
Following these transactions, he held 100 shares of common stock directly. The underlying options are from a grant that vested in three equal annual installments on the anniversary of the July 11, 2022 grant date and carry an expiration of 07/11/2032. The filing shows 22,818 derivative securities beneficially owned after the 11/06 activity.
Axogen, Inc. (AXGN): Director Form 4 activity
Director reported option exercises and same‑day open‑market sales under a Rule 10b5‑1(c) trading plan adopted March 14, 2025. On 10/29/2025, options for 20,436 shares were exercised at $6.30 and sold at a weighted average $19.1542 (shares sold at prices from $19.00 to $19.50). Also on 10/29/2025, options for 19,799 shares were exercised at $8.14 and sold at $22. On 10/30/2025, options for 18,248 shares were exercised at $7.04 and sold at $23.
Following these transactions, direct beneficial ownership of common stock was 100 shares. The $6.30 and $7.04 option grants show 0 remaining after exercise, while the $8.14 grant shows 39,596 derivative securities beneficially owned following the reported transactions.
Axogen (AXGN) reported Q3 2025 results. Revenue was $60,082, up 23.5% year over year, with gross profit of $45,993 and gross margin of 76.6%. The quarter delivered net income of $708 (diluted EPS $0.01) versus a loss a year ago, as sales and marketing investments supported higher volumes and pricing.
For the first nine months, revenue reached $165,304 and net loss was $2,547. Cash, cash equivalents and investments totaled $35,791 as of September 30, 2025. Management noted that discontinuing the Avance case stock program and moving some customers to direct orders increased Q3 revenue by about $1.6 million.
Industry tailwinds included new society statements from AAHS and ASRM recognizing nerve allograft as a standard option and broader payer coverage, adding approximately 18.1 million covered lives in 2025. The FDA accepted the BLA for Avance Nerve Graft and, after a major amendment, set a December 5, 2025 PDUFA goal date.
Axogen, Inc. furnished an 8-K announcing its third quarter 2025 financial results communications. The company issued a Q3 2025 earnings press release and posted a results presentation; these are furnished under Items 2.02 and 7.01, respectively.
The materials are available as Exhibit 99.1 (press release) and Exhibit 99.2 (presentation) dated October 29, 2025, and are furnished rather than filed. The presentation was also posted at https://ir.axogeninc.com/news-events.
Axogen, Inc. (AXGN): Form 4 insider transaction — A company director reported a sale of common stock on 10/22/2025. The filing shows 1,457 shares were sold at a weighted average price of $18.018 per share, with individual trades executed between $18.00 and $18.045.
The transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted on March 14, 2025. Following the sale, the reporting person beneficially owns 100 shares directly.
Axogen, Inc. (AXGN) director William P. Burke reported the sale of 736 shares of common stock on
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
